News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company also raised Rs 270 crore investment from Temasek in 2019
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
Upon closing, the Quakertown business will become an independent company called Microsize
Subscribe To Our Newsletter & Stay Updated
